Patent Assignment
Reel/Frame 046638/0466
Certificate of Change of Company's Address
Recorded: 2018-07-27
Pages: 8
Assignor
INTERMUNE, INC.
Executed: 2018-07-11
Assignee
INTERMUNE, INC.
C/O GENENTECH, INC., LEGAL DEPARTMENT, 1 DNA WAY, SOUTH SAN FRANCISCO, CALIFORNIA, 94080-4990
Covered Properties
(194)
Composition and Method for Reparation and Prevention of Fibrotic Lesions
Patent:
5,310,562 →
Application:
07/947,995 →
Inhibition of Tumor Necrosis Factor Alpha
Patent:
5,962,478 →
Application:
09/044,441 →
Treatment of Cytokine Growth Factor Caused Disorders
Patent:
6,090,822 →
Application:
09/162,011 →
Compositions and Method for Treatment of Lymphomas, Leukemias, and Leiomyomas
Patent:
6,114,353 →
Application:
09/239,211 →
Inhibition of Tumor Necrosis Factor Alpha
Patent:
6,300,349 →
Application:
09/364,562 →
Ameliorant for Hepatitis C Therapeutic Effect and Application Thereof
Patent:
6,455,051 →
Application:
09/529,303 →
Methods for Treatment of Benign and Malignant Tumors, Including Lymphomas, Leukemias, and Leiomyomas
Patent:
40,155 →
Application:
09/724,378 →
Compositions and Methods for Treatment of Epilepsy
Patent:
6,956,044 →
Application:
10/204,605 →
Ameliorant for hepatitis C therapeutic effect and application thereof
Application:
10/214,131 →
Publication:
US 2003/0003075
Medicinal Preparation Containing 5-Methyl-1-Phenyl-2-(1H)-Pyridone as Active Ingredient
Methods of treating liver fibrosis
Application:
10/483,938 →
Publication:
US 2004/0241138
Methods of treating liver fibrosis and hepatitis c virus infection
Application:
10/490,457 →
Publication:
US 2005/0013801
Methods of Treating Idiopathic Pulmonary Fibrosis
Application:
10/525,583 →
Publication:
US 2008/0057030
Combination therapy for treatment of fibrotic disorders
Application:
10/526,087 →
Publication:
US 2006/0110358
Marketing System for Improving Patient Compliance and Methods and Devices Relating to Same
Application:
10/543,466 →
Publication:
US 2008/0102056
Interferon drug therapy for the treatment of viral diseases and liver fibrosis
Application:
10/545,631 →
Compositions and methods for treating viral infections
Application:
10/552,020 →
Publication:
US 2006/0198823
Combination therapy for proliferative disorders
Application:
10/555,390 →
Synthetic chemokine receptor ligands and methods of use thereof
Application:
10/555,735 →
Publication:
US 2007/0172446
Combination therapy for cancer treatment
Application:
10/556,474 →
Publication:
US 2007/0032457
Interferon Gamma Therapies for Idiopathic Pulmonary Fibrosis
Application:
10/556,487 →
Publication:
US 2007/0160580
Methods of treating idiopathic pulmonary fibrosis
Application:
10/557,110 →
Publication:
US 2007/0092488
Methods of Treating Tnf-Mediated Disorders
Application:
10/557,647 →
Publication:
US 2008/0025986
Use of Pirfenidone in Therapeutic Regimens
Interferon compositions and methods of use thereof
Application:
11/153,864 →
Publication:
US 2006/0018875
Biomarkers for predicting liver fibrosis treatment efficacy
Application:
11/356,634 →
Publication:
US 2006/0198787
Use of Alpha-Glucosidase Inhibitors to Treat Alphavirus Infections
Method of Modulating Stress-Activated Protein Kinase System
Methods of treating idiopathic pulmonary fibrosis
Application:
11/487,733 →
Publication:
US 2007/0053877
Methods of reducing adverse events associated with pirfenidone therapy
Application:
11/605,199 →
Publication:
US 2007/0203202
High Throughput Collagen Synthesis Assay
Application:
11/761,500 →
Publication:
US 2008/0003635
Non-natural chemokine receptor ligands and methods of use thereof
Application:
11/913,768 →
Publication:
US 2009/0131312
Method of Providing Pirfenidone Therapy to a Patient
Altering Pharmacokinetics of Pirfenidone Therapy
Application:
12/020,068 →
Publication:
US 2008/0287508
Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients
Pirfenidone/Toll-Like Receptor (Tlr) Agonist Compounds and Methods of Treating Neutropenia
Application:
12/091,153 →
Publication:
US 2009/0170804
Methods of Treating Atrial Fibrillation with P38 Inhibitor Compounds
Application:
12/091,161 →
Publication:
US 2010/0029578
Method of Modulating Stress-Activated Protein Kinase System
Application:
12/094,230 →
Publication:
US 2011/0034495
Hcv Genotyping and Phenotyping
Application:
12/262,111 →
Publication:
US 2009/0220943
Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients
Method of Providing Pirfenidone Therapy to a Patient
Modifying Pirfenidone Treatment for Patients with Atypical Liver Function
Patent:
7,566,729 →
Application:
12/428,393 →
Compounds and Methods for Treating Inflammatory and Fibrotic Disorders
Modifying Pirfenidone Treatment for Patients with Atypical Liver Function
Application:
12/488,228 →
Pirfenidone Treatment for Patients with Atypical Liver Function
Patent:
7,635,707 →
Application:
12/553,292 →
Use of Alpha-Glucosidase Inhibitors to Treat Alphavirus Infections
Pirfenidone Therapy and Inducers of Cytochrome P450
Methods of Administering Pirfenidone Therapy
Patent:
7,816,383 →
Application:
12/684,879 →
Method of Modulating Stress-Activated Protein Kinase System
Application:
12/790,099 →
Publication:
US 2010/0240704
Method for Synthesizing Pirfenidone
Application:
12/792,387 →
Publication:
US 2011/0003863
Method of Providing Pirfenidone Therapy to a Patient
Methods of Administering Pirfenidone Therapy
Patent:
7,910,610 →
Application:
12/901,245 →
Pharmaceutical Composition Containing as an Active Ingredient 5-Methyl-1-Phenyl-2-(1H)-Pyridone
Application:
12/941,994 →
Publication:
US 2011/0104276
Pirfenidone/Toll-Like Receptor (TLR) Agonist Compounds and Methods of Treating Neutropenia
Application:
13/024,661 →
Publication:
US 2011/0218169
Use of Alpha-Glucosidase Inhibitors to Treat Alphavirus Infections
Application:
13/024,915 →
Publication:
US 2011/0177026
Altering Pharmacokinetics of Pirfenidone Therapy
Application:
13/028,827 →
Publication:
US 2011/0136876
Methods of Administering Pirfenidone Therapy
Pirfenidone Treatment for Patients with Atypical Liver Function
Granulate Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients
Methods of Administering Pirfenidone Therapy
Methods of Treating Atrial Fibrillation with P38 Inhibitor Compounds
Application:
13/244,707 →
Publication:
US 2012/0046321
Methods of Administering Pirfenidone Therapy
Application:
13/244,711 →
Publication:
US 2012/0015985
Methods of Treating Hiv Patients with Anti-Fibrotics
Application:
13/244,752 →
Publication:
US 2012/0014917
Method for Synthesizing Pirfenidone
Pirfenidone Treatment for Patients with Atypical Liver Function
Pirfenidone Derivatives for Treating Bronchial Asthma
Application:
13/318,568 →
Pirfenidone Therapy and Inducers of Cytochrome P450
Pharmaceutical Composition Containing as an Active Ingredient 5-Methyl-1-Phenyl-2-(1H)-Pyridone
Application:
13/333,142 →
Publication:
US 2012/0183615
Pirfenidone Therapy and Inducers of of Cytochrome P450
Method of Administering Pirfenidone Therapy
Application:
13/513,485 →
Publication:
US 2013/0030024
Method of Modulating Stress-Activated Protein Kinase System
Compounds and Methods for Treating Inflammatory and Fibrotic Disorders
Pharmaceutical Composition Containing as an Active Ingredient 5-Methyl-1-Phenyl-2-(1H)-Pyridone
Methods of Diagnosing and Treating Idiopathic Pulmonary Fibrosis
Application:
13/683,099 →
Publication:
US 2013/0150426
Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients
Anti-Fibrotic Pyridinones
Application:
13/799,727 →
Publication:
US 2014/0094456
Altering Pharmacokinetics of Pirfenidone Therapy
Application:
13/857,465 →
Publication:
US 2013/0225639
Method of Providing Pirfenidone Therapy to a Patient
Application:
13/861,099 →
Publication:
US 2013/0220871
Method for Synthesizing Pirfenidone
Application:
13/947,643 →
Publication:
US 2013/0345430
Methods of Administering Pirfenidone Therapy
Anti-Fibrotic Pyridinones
Pirfenidone Treatment for Patients with Atypical Liver Function
Application:
14/078,186 →
Publication:
US 2014/0073673
Altering Pharmacokinetics of Pirfenidone Therapy
Application:
14/246,414 →
Publication:
US 2014/0221434
Method for Synthesizing Pirfenidone
Application:
14/247,357 →
Publication:
US 2014/0221660
Method of Modulating Stress-Activated Protein Kinase System
Compounds and Methods for Treating Inflammatory and Fibrotic Disorders
Method for Preparing a Granulate Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients
Application:
14/271,720 →
Publication:
US 2014/0242159
Pirfenidone Therapy and Inducers of Cytochrome P450
Application:
14/276,368 →
Methods of Administering Pirfenidone Therapy
Application:
14/296,823 →
Pirfenidone Treatment for Patients with Atypical Liver Function
Application:
14/322,578 →
Pirfenidone and Anti-Fibrotic Therapy in Selected Patients
Application:
14/373,276 →
Publication:
US 2015/0164874
Anti-Fibrotic Pyridinones
Application:
14/432,881 →
Publication:
US 2015/0266899
Methods of Administering Pirfenidone Therapy
Application:
14/454,980 →
Publication:
US 2014/0350060
Compounds and Methods for Treating Inflammatory and Fibrotic Disorders
Patent:
47,142 →
Application:
14/534,450 →
Method for Synthesizing Pirfenidone
Application:
14/538,426 →
Publication:
US 2015/0065720
Pirfenidone Therapy and Inducers of Cytochrome P450
Application:
14/580,335 →
Publication:
US 2015/0111899
Methods of Administering Pirfenidone Therapy
Application:
14/599,130 →
Pharmaceutical Composition Containing as an Active Ingredient 5-Methyl -1-Phenyl-2-(1H)-Pyridone
Application:
14/671,251 →
Publication:
US 2015/0209341
Methods of Improving Microvascular Integrity
Pirfenidone Therapy and Inducers of Cytochrome P450
Application:
14/825,367 →
Publication:
US 2015/0342941
Method for Synthesizing Pirfenidone
Application:
14/830,999 →
Publication:
US 2015/0368200
Methods of Administering Pirfenidone Therapy
Application:
14/838,095 →
Pirfenidone Treatment for Patients with Atypical Liver Function
Application:
14/866,149 →
Pharmaceutical Composition Containing as an Active Ingredient 5-Methyl-1-Phenyl-2-(1H)-Pyridone
Methods of Administering Pirfenidone Therapy
Application:
15/098,233 →
Publication:
US 2016/0228423
Anti-Fibrotic Pyridinones
Pirfenidone Treatment for Patients with Atypical Liver Function
Application:
15/148,792 →
Publication:
US 2016/0250198
Anti-Fibrotic Pyridinones
Methods of Administering Pirfenidone Therapy
Application:
15/179,279 →
Publication:
US 2016/0303098
Method of Providing Pirfenidone Therapy to a Patient
Application:
15/212,674 →
Publication:
US 2016/0324842
Methods of Administering Pirfenidone Therapy
Application:
15/366,225 →
Publication:
US 2017/0079969
Pharmaceutical Composition Containing as an Active Ingredient 5-Methyl-1-Phenyl-2-(1H)-Pyridone
Application:
15/385,451 →
Publication:
US 2017/0100380
Method of Modulating Stress-Activated Protein Kinase System
Pirfenidone Treatment for Patients with Atypical Liver Function
Application:
15/388,902 →
Publication:
US 2017/0100381
Methods of Administering Pirfenidone Therapy
Application:
15/412,923 →
Publication:
US 2017/0128429
Granulate Formulation of 5-Methyl-1-Phenyl-2-(1H)-Pyridone and Method of Making the Same
Anti-Fibrotic Pyridinones
Methods of Administering Pirfenidone Therapy
Application:
15/648,133 →
Pirfenidone Treatment for Patients with Atypical Liver Function
Application:
15/669,552 →
Publication:
US 2017/0333411
Methods of Administering Pirfenidone Therapy
Application:
15/809,511 →
Publication:
US 2018/0064695
Method of Providing Pirfenidone Therapy to a Patient
Application:
15/874,590 →
Publication:
US 2018/0140588
Methods of Administering Pirfenidone Therapy
Application:
15/898,961 →
Publication:
US 2018/0169084
Pirfenidone Treatment for Patients with Atypical Liver Function
Application:
15/918,685 →
Publication:
US 2018/0200242
Granulate Formulation of 5-Methyl-1-Phenyl-2-(1H)-Pyridone and Method of Making the Same
Application:
15/967,415 →
Publication:
US 2018/0243277
Methods of Administering Pirfenidone Therapy
Application:
16/020,508 →
Publication:
US 2018/0311221
Methods of treating liver fibrosis
Application:
60/307,013 →
Methods of treating liver fibrosis and hepatitis C virus infection
Application:
60/327,743 →
Methods of treating idiopathic pulmonary fibrosis
Application:
60/406,515 →
Combination therapy for treatment of fibrotic disorders
Application:
60/406,901 →
Marketing system for improving patient compliance and methods and devices relating to same
Application:
60/444,813 →
Compositions and methods for treating viral infections
Application:
60/460,194 →
Type I interferon receptor agonists and IP-10 combination therapy for cancer treatment
Application:
60/471,043 →
IP-10 and pirfenidone combination therapy for cancer treatment
Application:
60/471,129 →
Pirfenidone combination therapy for cancer treatment
Application:
60/471,179 →
Methods of treating idiopathic pulmonary fibrosis
Application:
60/471,199 →
Type I interferon receptor agonist and pirfenidone combination therapy for cancer treatment
Application:
60/471,249 →
Hybrid chemokine receptor ligands and methods of use thereof
Application:
60/471,404 →
Combination IFN therapy
Application:
60/471,841 →
Interferon gamma therapies for idiopathic pulmonary fibrosis
Application:
60/471,862 →
Methods of treating TNF-mediated disorders
Application:
60/476,711 →
Combination IFN therapy for proliferative disorders
Application:
60/485,474 →
Combination therapy for the treatment of viral diseases
Application:
60/511,169 →
Combination therapy for the treatment of fibrotic diseases
Application:
60/511,259 →
Combination therapy for the treatment of fibrotic diseases
Application:
60/511,280 →
Interferon-gamma and TNF-alpha antagonist combination therapy for the treatment of fibrotic diseases
Application:
60/511,415 →
Use of pirfenidone in therapeutic regimens
Application:
60/514,052 →
Combination therapy for treating proliferative disorders
Application:
60/514,173 →
Interferon gamma therapies for idiopathic pulmonary fibrosis
Application:
60/554,774 →
Combination therapy for treating fibrotic disorders
Application:
60/561,940 →
Interferon compositions and methods of use thereof
Application:
60/579,625 →
Biomarkers for predicting liver fibrosis treatment efficacy
Application:
60/654,166 →
Use of alpha-glucosidase inhibitors to treat alphavirus infections
Application:
60/660,074 →
Method of modulating stress-activated protein kinase system
Application:
60/679,471 →
Non-natural chemokine receptor ligands and methods of use thereof
Application:
60/682,544 →
Use of alpha-glucosidase inhibitors to treat alphavirus infections
Application:
60/707,891 →
Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
Application:
60/720,257 →
Pirfenidone/toll-like receptor (TLR) agonist compositions and methods for using them to stimulate production of granulocyte colonizing stimulating factor (G-CSF)
Application:
60/731,661 →
Method of modulating stress-activated protein kinase system
Application:
60/732,230 →
Methods of treating atrial fibrillation with p38 inhibitor compounds
Application:
60/732,676 →
Method of modulating stress-activated protein kinase system
Application:
60/739,315 →
Methods of reducing adverse events associated with pirfenidone therapy
Application:
60/741,976 →
Method of modulating stress-activated protein kinase system
Application:
60/775,823 →
Method of modulating stress-activated protein kinase system
Application:
60/793,526 →
Method of Providing Pirfenidone Therapy to a Patient
Application:
60/870,593 →
Altering Pharmacokinetics of Pirfenidone Therapy
Application:
60/938,850 →
Hcv Genotyping and Phenotyping Assays
Application:
60/983,854 →
Hcv Genotyping and Phenotyping
Application:
61/043,020 →
Compounds and Methods for Treating Inflammatory and Fibrotic Disorders
Application:
61/058,436 →
Compounds and Methods of Treating Inflammatory and Fibrotic Disorders
Application:
61/074,446 →
Modifying Pirfenidone Treatment for Patients with Atypical Liver Function
Application:
61/113,107 →
Methods of Controlling Fibrosis in HIV Patients
Application:
61/178,786 →
Pirfenidone Analogs Prevent Allergen-Induced Airway Hyperresponsiveness (AHR) and Inflammation
Application:
61/179,617 →
Method for Synthesizing Pirfenidone
Application:
61/183,588 →
Modifying pirfenidone treatment for patients with atypical liver function
Application:
61/228,943 →
Pirfenidone Therapy and Inducers of Cytochrome P450
Application:
61/266,753 →
Methods of Administering Pirfenidone Therapy
Application:
61/266,815 →
Pirfenidone Therapy and Inducers of Cytochrome P450
Application:
61/310,575 →
Methods of Administering Pirfenidone Therapy
Application:
61/310,679 →
Pirfenidone Therapy in Selected Patients
Application:
61/489,936 →
Pirfenidone and Anti-Fibrotic Therapy in Selected Patients
Application:
61/490,057 →
Pirfenidone and Anti-Fibrotic Therapy in Selected Patients
Application:
61/523,047 →
Pirfenidone and Anti-Fibrotic Therapy in Selected Patients
Application:
61/524,961 →
Methods for Diagnosing and Treating Idiopathic Pulmonary Fibrosis
Application:
61/562,770 →
Methods for Diagnosing and Treating Idiopathic Pulmonary Fibrosis
Application:
61/648,548 →
Methods Of Administering Pirfenidone Therapy
Application:
61/696,044 →
Methods of Administering Pirfenidone Therapy
Application:
61/709,125 →
Methods of Administering Pirfenidone Therapy
Application:
61/749,026 →
Methods of Administering Pirfenidone Therapy
Application:
61/775,240 →
Methods of Improving Microvascular Integrity
Application:
61/793,035 →
Methods of Administering Pirfenidone Therapy
Application:
61/842,706 →
Anti-Fibrotic Pyridinones
Application:
61/974,334 →
Granulate Formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same
Application:
62/314,933 →
Methods of Administering Anti-Fibrotic Therapy
Application:
62/428,163 →
Methods of Administering Anti-Fibrotic Therapy
Application:
62/432,425 →
Related Assignments
(1)
Other recorded transfers of the patents in this record — the chain of ownership.